Latest Industry Insights

Technology Networks recently spoke with Paul Brennan, President and CEO at NervGen Pharma, to gain his insights on why previous attempts to treat Alzheimer's disease have failed, how the novel technology platform NVG-291 works and what promise it holds for AD.

In this article, we discuss current examples of how motion capture technology can be applied across the life sciences industry.

Immune dysregulation plays a central role in many pathologies. We spoke with Dr Fabienne Charrier-Savournin, from Cisbio, to learn more about the mechanisms underpinning immune dysregulation and how this knowledge is applied for therapeutic intervention.

Recently, Thermo Fisher Scientific announced its membership of the Pistoia Alliance. At the Lab of the Future Congress 2019, we spoke with members of the Thermo Fisher team to learn more about the goals of joining the alliance, and what innovation means to Thermo Fisher.

As a stalwart in the biological and chemical analysis fields, JEOL celebrates its 70th anniversary this year. But that’s not all it is celebrating, with the appointment of 35-year veteran of JEOL USA, Bob Pohorenec as President of the company this year.

Trisha Rice, VP & GM Materials Science Business at Thermo Fisher Scientific, shares her experiences as a woman in science, and provides tips on how to be your most "authentic self" in the field.

We spoke to Daniel Rooke, Head of Operations and Legal at Start Codon, to learn more about the company and how they can help early stage healthcare and life science businesses in the UK to get off the ground.

We recently had the pleasure of interviewing Paul-Peter Tak, CEO of Kintai Therapeutics. Tak discusses how Kintai Therapeutics are exploiting the power of big data and machine learning to unravel the interconnected biology of the gut, and explains how the enteric signaling network can be therapeutically targeted.

Neurodegenerative diseases are one of the most pressing challenges of our time and teasing out the cellular mechanisms underpinning these diseases is a key goal for researchers in the field. We talked to Stéphane Martinez of CISBIO to discuss how researchers can access information on neurodegenerative mechanisms and how we are beginning to recognize the contribution of the immune system to neurodegeneration.

To learn more about AC Immune's series of compounds designed to target tau aggregation, we recently spoke with Prof. Andrea Pfeifer, the company's Chief Executive Officer.